ReviewJapanese journal of clinical oncology2021
Transarterial management of advance lung cancer.
Review in Japanese journal of clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 15 citations in OpenAlex.
- Hydrogel-based tumor embolization and synergistic therapeutic strategies.Bioactive materials · 2026Review
- The impact of pulmonary artery invasion on bronchial artery embolization in treating hemoptysis in lung cancer.European journal of radiology open · 2025Article
- Narrative review of the progress in the treatment of hemoptysis among patients with advanced lung cancer.Journal of thoracic disease · 2025Review
- Drug-eluting beads bronchial arterial chemoembolization in advanced and standard treatment-refractory/ineligible non-small cell lung cancer.Quantitative imaging in medicine and surgery · 2025Article
- Transcatheter arterial chemoembolization for lung malignant tumors.Frontiers in oncology · 2025Review
- Clinical study on bronchial artery chemoembolization for unresectable non-small cell lung cancer.Frontiers in oncology · 2025Article
- An Interventional Radiologist's Guide to Lung Cancer.Seminars in interventional radiology · 2024Review
- Efficacy and safety of CalliSpheres drug-eluting beads for bronchial arterial chemoembolization for refractory non-small-cell lung cancer and its impact on quality of life: A multicenter prospective study.Frontiers in oncology · 2023Article
- Transarterial Treatment of Lung Cancer.Life (Basel, Switzerland) · 2022Article
- Image-Guided Percutaneous and Transarterial Therapies for Primary and Metastatic Lung Cancer.Technology in cancer research & treatmentReview
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous reports on transarterial treatment for lung cancer were reviewed. The bronchial arterial infusion therapy has a long history since 1964. Better local control with less doses of anti-neoplastic agents was warranted by trying transarterial administration to lung and mediastinal tumors. It is reported that both primary and metastatic tumors are fed by bronchial or other systemic arteries. The bronchial arterial embolization for hemoptysis has been introduced for clinical practice since 1973. Hemoptysis by not only benign but also malignant diseases has been well controlled by embolization. In recent decades, the technical elements for transarterial treatments have markedly improved. They make it possible to carry out precise procedures of selective catheter insertion to the tumor relating arteries. Current concepts of transarterial treatment, technical aspects and treatment outcomes are summarized. Tentative result from chemo-embolization for advanced lung cancer using recent catheter techniques was also described. It provides favorable local control and survival merits. It is considered that a population of lung cancer patients can benefit from transarterial management using small doses of anti-neoplastic agents, with less complications and less medical costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.